enGene Holdings Inc News - ENGN

Professional-Grade Tools, for Individual Investors.

enGene to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference

enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational...

enGene Announces $60 Million Private Placement Financing

enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational...

enGene Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational...

enGene Appoints Joan Connolly as Chief Technology Officer and Anthony Cheung, Ph.D., as Chief Scientific Officer

enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational...

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational...

Detalimogene Demonstrates 71% Complete Response Rate at Any Time in Preliminary Analysis of LEGEND Pivotal Cohort

Data from pivotal cohort demonstrate compelling clinical activity, consistent with Phase 1 results Favorable tolerability profile with no...

enGene Reports Third Quarter 2024 Financial Results and Provides a Business Update

Company remains on track to report preliminary LEGEND data in September 2024 Cash and cash equivalents of $257.7 million provide runway into...

enGene to Participate in Upcoming Investor Conferences

enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead program...

enGene Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral, intravesical lead...

enGene Announces Appointment of Ron Cooper as Chief Executive Officer

Ron Cooper succeeds Jason Hanson as Chief Executive Officer and Director Company also announces Dr. Raj Pruthi’s promotion to Chief Medical...

NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors

NAARDEN, The Netherlands and MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V...

enGene Reports Second Quarter 2024 Financial Results and Provides a Business Update

Company announces plans for initial indication expansion for EG-70 into high-risk papillary-only NMIBC enGene Holdings Inc. (Nasdaq: ENGN...

enGene to Present at the Jefferies Global Healthcare Conference

enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead program EG-70...

enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors

enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead program EG-70...

enGene to Present Details of its Pivotal Phase 1/2 LEGEND Study of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ at the American Urology Association 2024 Annual Meeting

enGene to Present Details of its Pivotal Phase 1/2 LEGEND Study of EG-70 in BCG-Unresponsive Non-Muscle...

mick 3 months ago

https://www.otcmarkets.com/stock/ENGN/security LOT OF SHARES

👍️0

mick 3 months ago

ENGN
enGene Holdings Inc
8.38
-0.43 (-4.88%)
Volume: 79,733
Day Range: 8.07 - 9.4712
Last Trade Time: 4:00:02 PM EDT
Delayed by 15 minutes

👍️0

Monksdream 4 months ago

ENGN under $10

👍️0

jump1 11 months ago

$6.73 add for tomorrow.

👍️0

jump1 11 months ago

88,000 V and down 23 percent if that isn’t the biggest corrupt thing right before your eyes. Will keep adding drop another 23% tomorrow add again.

👍️0

dinogreeves 11 months ago

A great patent and low float, could hit big numbers with volume. Could be the runner, runner this week.

🪦 1 ⚰️ 1

dinogreeves 11 months ago

Possible short squeeze to 20...25....30. Just needs volume with this small float.

🤥 1 🪦 1 ⚰️ 1

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

enGene Holdings Inc (ENGN)

Professional-Grade Tools, for Individual Investors.

ENGN News

enGene to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference

enGene Announces $60 Million Private Placement Financing

enGene Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

enGene Appoints Joan Connolly as Chief Technology Officer and Anthony Cheung, Ph.D., as Chief Scientific Officer

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Detalimogene Demonstrates 71% Complete Response Rate at Any Time in Preliminary Analysis of LEGEND Pivotal Cohort

enGene Reports Third Quarter 2024 Financial Results and Provides a Business Update

enGene to Participate in Upcoming Investor Conferences

enGene Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

enGene Announces Appointment of Ron Cooper as Chief Executive Officer

NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors

enGene Reports Second Quarter 2024 Financial Results and Provides a Business Update

enGene to Present at the Jefferies Global Healthcare Conference

enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors

enGene to Present Details of its Pivotal Phase 1/2 LEGEND Study of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ at the American Urology Association 2024 Annual Meeting

ENGN Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

enGene Holdings Inc (ENGN) News

enGene Holdings Inc (ENGN)

Professional-Grade Tools, for Individual Investors.

ENGN News

enGene to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference

enGene Announces $60 Million Private Placement Financing

enGene Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

enGene Appoints Joan Connolly as Chief Technology Officer and Anthony Cheung, Ph.D., as Chief Scientific Officer

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Detalimogene Demonstrates 71% Complete Response Rate at Any Time in Preliminary Analysis of LEGEND Pivotal Cohort

enGene Reports Third Quarter 2024 Financial Results and Provides a Business Update

enGene to Participate in Upcoming Investor Conferences

enGene Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

enGene Announces Appointment of Ron Cooper as Chief Executive Officer

NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors

enGene Reports Second Quarter 2024 Financial Results and Provides a Business Update

enGene to Present at the Jefferies Global Healthcare Conference

enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors

enGene to Present Details of its Pivotal Phase 1/2 LEGEND Study of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ at the American Urology Association 2024 Annual Meeting

ENGN Discussion

Your Recent History